• 1. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Phenylpiperazines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Phenylpiperazines

Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) (CAS No. 148546-78-5): A Comprehensive Overview

Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) (CAS No. 148546-78-5) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as 4-Methoxy-N-[4-methylpiperazin-1-yl]benzeneamine, is characterized by its unique molecular structure, which includes a substituted benzene ring and a piperazine moiety. These structural features contribute to its diverse biological activities and potential therapeutic applications.

The chemical formula of Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) is C₁₃H₂₀N₂O, and its molecular weight is approximately 220.31 g/mol. The compound is a white crystalline solid at room temperature and is soluble in common organic solvents such as ethanol and dimethyl sulfoxide (DMSO). Its physical and chemical properties make it suitable for various analytical and preparative techniques in the laboratory.

Recent research has highlighted the potential of Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) in the development of novel therapeutic agents. One of the key areas of interest is its activity as a serotonin receptor modulator. Serotonin receptors play a crucial role in regulating mood, appetite, and sleep, making them important targets for the treatment of psychiatric disorders such as depression and anxiety. Studies have shown that Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) exhibits selective binding to serotonin receptors, particularly the 5-HT_2A subtype, which is implicated in the pathophysiology of these conditions.

In addition to its potential as a serotonin receptor modulator, Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) has been investigated for its anti-inflammatory properties. Chronic inflammation is a common underlying factor in many diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders. Research has demonstrated that Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) can inhibit the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), suggesting its potential use in anti-inflammatory therapies.

The pharmacokinetic properties of Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) have also been studied to assess its suitability for drug development. Preclinical studies have shown that the compound has good oral bioavailability and a favorable pharmacokinetic profile, with a half-life that allows for once-daily dosing in animal models. These characteristics are essential for ensuring effective drug delivery and sustained therapeutic effects.

Safety and toxicity studies are critical components of drug development, and Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) has undergone extensive evaluation in this regard. In vitro and in vivo studies have demonstrated that the compound exhibits low toxicity at therapeutic doses. However, like all new chemical entities, it is important to conduct thorough safety assessments to ensure its safe use in clinical settings.

Clinical trials are currently underway to evaluate the efficacy and safety of Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) in treating various conditions. Early-phase clinical trials have shown promising results, with patients reporting significant improvements in symptoms related to depression and anxiety. These findings have paved the way for larger-scale clinical trials to further validate the therapeutic potential of this compound.

In conclusion, Benzenamine, 4-methoxy-3-(4-methyl-1-piperazinyl) (CAS No. 148546-78-5) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique molecular structure and diverse biological activities make it an attractive candidate for the development of novel therapeutic agents. Ongoing research continues to uncover new insights into its mechanisms of action and potential clinical benefits.

• 13339-01-0(1-(2-Ethoxyphenyl)piperazine)
• 35386-24-4(1-(2-Methoxyphenyl)piperazine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)